Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials | Zendy

Li Wang | Zendy; Chen Di Liao | Zendy; Meng Li | Zendy; Shujuan Zhang | Zendy; Fengming Yi | Zendy; Yiping Wei | Zendy; Jiao Yu | Zendy; Wenxiong Zhang | Zendy

Open Access

Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials

Author(s) -

Li Wang,

Chen Di Liao,

Meng Li,

Shujuan Zhang,

Fengming Yi,

Yiping Wei,

Jiao Yu,

Wenxiong Zhang

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-19-365

Subject(s) - medicine , meta analysis , cochrane library , lung cancer , oncology , rash , chemotherapy , randomized controlled trial , adverse effect , confidence interval , hazard ratio , progression free survival

Whether necitumumab combined with platinum-based chemotherapy (NC) for treating stage IV non-small cell lung cancer (NSCLC) as a first-line treatment could enhance antitumor effectiveness compared with platinum-based chemotherapy alone (CA) treatment is still controversial. The antitumor effectiveness and toxicity of the two treatments were compared in this meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research